Trial Profile
A Randomized, Double-blind, Placebo-Controlled, Study of the Safety and Efficacy of RGN-352 in Subjects With an Acute ST Elevation Myocardial Infarction (STEMI) After Occlusion of the Proximal Left Anterior Descending Coronary Artery.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2021
Price :
$35
*
At a glance
- Drugs Timbetasin (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Sponsors RegeneRx Biopharmaceuticals
- 15 Sep 2021 Planned End Date changed from 1 Aug 2014 to 1 Jul 2020.
- 15 Sep 2021 Planned initiation date changed from 1 Mar 2013 to 1 Jul 2019.
- 15 Sep 2021 Status changed from suspended to withdrawn prior to enrolment because the trial was never initiated.